Literature DB >> 18421545

Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus.

Cecilia P Chung1, Annette Oeser, Paolo Raggi, Joseph F Solus, Ingrid Avalos, MacRae F Linton, Sergio Fazio, C Michael Stein.   

Abstract

Patients with systemic lupus erythematosus (SLE) have accelerated atherosclerosis, but the underlying mechanisms are unclear. The size and number of lipoprotein particles may be better predictors of atherosclerosis than conventional cholesterol measurements. We measured lipoprotein subclasses by nuclear magnetic resonance spectroscopy (NMR), coronary artery calcification by electron beam computed tomography, and insulin resistance by homeostasis model assessment in 105 patients with SLE and 77 control subjects. VLDL particles were larger (50.0+/-8.5 versus 47.7+/-8.5 nm, P=0.01) and concentrations of large high-density lipoprotein (HDL) particles lower (10.1+/-5.3 versus 11.3+/-5.1 nmol/L, P=0.03) in patients with SLE than controls. In patients with SLE, small LDL concentration was associated with body mass index (rho=0.27), insulin resistance (rho=0.34), C-reactive protein (CRP; rho=0.30), and erythrocyte sedimentation rate (ESR; rho=0.20); all P<0.05. Large HDL concentration was inversely associated with insulin resistance (rho=-0.29), disease activity (rho=-0.23), and ESR (rho=-0.39); all P<0.05. VLDL concentrations correlated with CRP (rho=0.22), ESR (rho=0.24), disease damage (rho=0.20), and corticosteroid exposure (rho=0.29); all P<0.05. Neither the concentration of lipoprotein subclasses nor particle size was associated with coronary artery atherosclerosis. There were only minor differences in the NMR lipid profiles of patients with SLE and controls. Lipoprotein subclasses were associated with metabolic variables, inflammatory markers, and corticosteroid use but not with coronary artery atherosclerosis in SLE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18421545     DOI: 10.1007/s10067-008-0890-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  39 in total

1.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies.

Authors:  E F Borba; E Bonfá
Journal:  Lupus       Date:  1997       Impact factor: 2.911

2.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

3.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.

Authors:  T J Lyons; A J Jenkins; D Zheng; R L Klein; J D Otvos; Y Yu; D T Lackland; D McGee; M B McHenry; M Lopes-Virella; W T Garvey
Journal:  Diabet Med       Date:  2006-09       Impact factor: 4.359

5.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Authors:  Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

6.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.

Authors:  Robert S Rosenson; James D Otvos; David S Freedman
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

7.  Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus.

Authors:  Faith Selzer; Kim Sutton-Tyrrell; Shirley G Fitzgerald; Joan E Pratt; Russell P Tracy; Lewis H Kuller; Susan Manzi
Journal:  Arthritis Rheum       Date:  2004-01

8.  Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study.

Authors:  Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-07-01       Impact factor: 8.311

Review 9.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

10.  Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease.

Authors:  D S Freedman; J D Otvos; E J Jeyarajah; J J Barboriak; A J Anderson; J A Walker
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-07       Impact factor: 8.311

View more
  9 in total

1.  LDL particle size and number compared with LDL cholesterol and risk categorization in end-stage renal disease patients.

Authors:  Rodney G Bowden; Ronald L Wilson; A Alexander Beaujean
Journal:  J Nephrol       Date:  2011 Nov-Dec       Impact factor: 3.902

Review 2.  Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk.

Authors:  George A Robinson; Ines Pineda-Torra; Coziana Ciurtin; Elizabeth C Jury
Journal:  Front Med (Lausanne)       Date:  2022-05-31

3.  GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus.

Authors:  C P Chung; M J Ormseth; M A Connelly; A Oeser; J F Solus; J D Otvos; P Raggi; C M Stein
Journal:  Lupus       Date:  2015-12-03       Impact factor: 2.911

4.  The effects of exercise on lipid profile in systemic lupus erythematosus and healthy individuals: a randomized trial.

Authors:  Fabiana Braga Benatti; Renata Miossi; Marisa Passareli; Edna R Nakandakare; Luiz Perandini; Fernanda Rodrigues Lima; Hamilton Roschel; Eduardo Borba; Eloisa Bonfá; Bruno Gualano; Ana Lúcia de Sá Pinto
Journal:  Rheumatol Int       Date:  2014-06-28       Impact factor: 2.631

5.  Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy.

Authors:  Laura Durcan; Deborah A Winegar; Margery A Connelly; James D Otvos; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2016-02-01       Impact factor: 4.666

Review 6.  HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases.

Authors:  Fabrizia Bonacina; Angela Pirillo; Alberico L Catapano; Giuseppe D Norata
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

7.  Dyslipidaemia in rheumatological autoimmune diseases.

Authors:  Tracey E Toms; Vasileios F Panoulas; George D Kitas
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

8.  Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE.

Authors:  Monica M Purmalek; Philip M Carlucci; Amit K Dey; Maureen Sampson; Yenealem Temesgen-Oyelakin; Simantini Sakhardande; Joseph B Lerman; Alice Fike; Michael Davis; Jonathan H Chung; Taufiq Salahuddin; Zerai Manna; Sarthak Gupta; Marcus Y Chen; Sarfaraz Hasni; Nehal N Mehta; Alan Remaley; Mariana J Kaplan
Journal:  Lupus Sci Med       Date:  2019-07-12

Review 9.  High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy.

Authors:  Sang Yeop Kim; Minzhi Yu; Emily E Morin; Jukyung Kang; Mariana J Kaplan; Anna Schwendeman
Journal:  Arthritis Rheumatol       Date:  2019-11-26       Impact factor: 10.995

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.